Financial Performance - The company's operating revenue for Q1 2023 was ¥57,808,350.06, representing a 41.10% increase compared to ¥40,969,366.74 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥1,569,616.07, which is a 9.65% increase in loss from ¥1,431,517.79 in the previous year[5] - The net profit for Q1 2023 was -1,573,833.18 yuan, compared to -1,390,574.95 yuan in Q1 2022, indicating a year-over-year decline of approximately 13.2%[21] - The total comprehensive income for Q1 2023 was -1,573,833.18 yuan, compared to -1,390,574.95 yuan in Q1 2022, indicating a worsening of overall financial performance[21] - Operating profit for Q1 2023 was -1,033,325.14 yuan, an improvement from -1,604,123.47 yuan in the same period last year[21] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥4,964,205.21, a decline of 252.57% compared to a positive cash flow of ¥3,253,639.09 in the same period last year[5] - Cash flow from operating activities showed a net outflow of -4,964,205.21 yuan, compared to a net inflow of 3,253,639.09 yuan in Q1 2022, reflecting a significant decrease in cash generation[22] - The company reported a cash and cash equivalents balance of 48,644,166.16 yuan at the end of Q1 2023, down from 81,636,641.01 yuan at the end of Q1 2022, a decrease of approximately 40.4%[23] - The company's cash and cash equivalents decreased to CNY 48,644,166.16 from CNY 56,249,276.14 at the beginning of the year, reflecting a cash outflow[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥297,980,795.42, an increase of 3.93% from ¥286,706,539.83 at the end of the previous year[5] - The total liabilities increased to CNY 205,015,642.58 from CNY 192,258,417.77 at the start of the year, indicating a rise in financial obligations[18] - The total equity attributable to shareholders decreased by 1.91% to ¥76,355,219.95 from ¥77,839,963.09 at the end of the previous year[5] - The total equity attributable to shareholders decreased to CNY 76,355,219.95 from CNY 77,839,963.09, reflecting a decline in retained earnings[18] Revenue and Costs - The total operating costs for Q1 2023 were CNY 58,304,382.79, up 33.1% from CNY 43,785,047.86 in Q1 2022[20] - The gross profit margin decreased, with operating costs rising significantly, particularly in the cost of goods sold, which was CNY 50,971,052.98 compared to CNY 37,570,442.29 last year[20] - Total revenue from sales of goods and services was 61,979,849.83 yuan, up from 57,441,722.83 yuan in the previous year, marking an increase of approximately 4.3%[22] Research and Development - The company's research and development expenses increased by 57.74% to ¥1,464,534.36 from ¥928,434.65 in the previous year, indicating a focus on innovation[10] - Research and development expenses increased to 1,464,534.36 yuan, up from 928,434.65 yuan, representing a year-over-year increase of about 57.6%[21] Other Financial Metrics - The basic earnings per share decreased by 10.26% to -¥0.0043 from -¥0.0039 in the previous year[5] - The company received government subsidies amounting to ¥79,594.63, a decrease of 68.22% from ¥250,441.27 in the previous year[10] - The company reported a net loss in retained earnings of CNY -808,522,462.16, slightly worsening from CNY -806,952,846.09 at the beginning of the year[18] - The company incurred financial expenses of 973,773.75 yuan, slightly down from 1,015,099.32 yuan in the previous year[21] Inventory and Accounts Receivable - The accounts receivable increased by 82.76% to ¥25,613,622.71 from ¥14,015,122.75, primarily due to increased sales and delayed customer payments[9] - Inventory levels decreased to CNY 32,091,735.60 from CNY 36,731,889.45, indicating a reduction in stock on hand[17] Operational Developments - The company is preparing for trial production at its newly constructed production line and multifunctional pilot workshop, which is expected to enhance operational capacity[14] - The cash outflow from investing activities was -2,573,515.85 yuan, compared to a net inflow of 42,718,772.62 yuan in Q1 2022, indicating a shift in investment strategy[22]

证券代码：000953 证券简称：河化股份 公告编号：2023-016 广西河池化工股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏。 广西河池化工股份有限公司（以下简称"公司"）于 2023 年 4 月 20 日在巨潮资讯网（www.cninfo.com.cn）披露了《2022 年年度报告》及 《2022 年年度报告摘要》。 二、投资者问题征集 为提升公司与投资者交流的针对性和有效性，现就公司本次业绩说 明会提前向投资者公开征集问题，广泛听取投资者的意见和建议，投资 者可于网上业绩说明会开始前 5 个交易日内登录深圳证券交易所"互动 易"平台"云访谈"栏目（http://irm.cninfo.com.cn），进入问题征集 页面提出问题。公司将在本次业绩说明会上，对投资者普遍关注的问题 进行回答。 欢迎广大投资者积极参与。 特此公告。 广西河池化工股份有限公司董事会 2023 年 4 月 25 日 为便于广大投资者进一步了解公司 2022 年度经营情况，公司定于 2023 年 5 月 9 日通过深圳证券 ...

Financial Performance - The company's operating revenue for 2022 was ¥160,612,375.12, a decrease of 1.02% compared to ¥162,273,039.66 in 2021[23]. - The net profit attributable to shareholders was -¥100,436,899.14, representing a decline of 1,102.53% from a profit of ¥10,018,330.39 in the previous year[23]. - The net cash flow from operating activities was ¥799,521.87, down 88.09% from ¥6,710,748.57 in 2021[23]. - The basic earnings per share were -¥0.27, a decrease of 1,000.00% compared to ¥0.03 in 2021[23]. - Total assets at the end of 2022 were ¥286,706,539.83, a reduction of 27.67% from ¥396,411,315.40 at the end of 2021[23]. - The net assets attributable to shareholders decreased by 56.13% to ¥77,839,963.09 from ¥177,419,002.38 in 2021[23]. - The company reported a significant decline in both net profit and cash flow, indicating potential challenges in sustaining operations[23]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the audit report[23]. Revenue Breakdown - The company's total revenue for Q1 2022 was approximately ¥40.97 million, while Q2 revenue increased to ¥52.94 million, followed by a decline to ¥37.98 million in Q3 and further down to ¥28.72 million in Q4[28]. - The net profit attributable to shareholders was negative in all quarters, with Q1 at -¥1.43 million, Q2 at ¥3.07 million, Q3 at -¥5.73 million, and Q4 at -¥96.34 million[28]. - The net cash flow from operating activities showed a positive trend in Q1 and Q2 at ¥3.25 million and ¥9.14 million respectively, but turned negative in Q3 and Q4, recording -¥8.86 million and -¥2.74 million[28]. - The company's revenue from the pharmaceutical intermediates segment was CNY 50,256,563.62, a decrease of 43.97% year-on-year, with a gross margin of 20.84%[52]. - The fertilizer business generated revenue of CNY 109,535,068.83, an increase of 60.39% year-on-year, with a gross margin of 1.27%[52]. - Domestic sales accounted for 86.96% of total revenue, amounting to CNY 139,672,115.12, reflecting a 24.15% increase year-on-year[52]. Research and Development - The company plans to increase investment in R&D and market expansion to diversify its product offerings and explore new fields, particularly in CDMA projects[35]. - The company has maintained a strong focus on R&D, with a dedicated team working on new product development and process optimization[44]. - Research and development expenses decreased by 44.45% to CNY 4,279,280.23 due to a reduction in R&D projects[60]. - The company plans to develop new processes for the synthesis of dezocine intermediates, aiming for industrial production to expand its product range[61]. - The company invested a total of ¥34,365,988.23 in the construction of a multifunctional pilot workshop, achieving 100% completion but with no realized revenue yet[75]. Corporate Governance - The company held three shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[92]. - The company has established an independent financial department with a complete financial accounting system, ensuring no interference from the controlling shareholder in financial activities[96]. - The company has established a sound corporate governance structure, continuously improving its governance level in compliance with relevant laws and regulations[94]. - The board of directors actively participated in meetings, with no director raising objections to company matters during the reporting period[120]. - The company has implemented strict insider information management to prevent any leakage of sensitive information during reporting periods[95]. Environmental Responsibility - The company holds a valid Pollutant Discharge Permit, effective from April 10, 2021, to April 9, 2026[137]. - The company has achieved zero exceedance in pollutant emissions throughout the year, as confirmed by self-monitoring reports[141]. - The company has been rated as an environmentally friendly enterprise by the Chongqing Ecological Environment Bureau during the reporting period[144]. - The company has invested approximately CNY 390,000 in optimizing and upgrading its waste gas treatment facilities and wastewater treatment station during the reporting period[143]. - The company has implemented a two-level spray adsorption + low-temperature plasma + activated carbon adsorption process for its waste gas treatment facilities[143]. Shareholder Information - The company has a total of 30,776 shareholders at the end of the reporting period, with significant shareholders including Ningbo Yinyi Holdings with 23.76% and Guangxi Hechi Chemical Industry Group with 10.24%[192]. - The company reported that 87,000,000 shares held by Ningbo Yinyi Holdings are pledged, and 37,493,589 shares held by Guangxi Hechi Chemical Industry Group are frozen[192]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 241.03 million[117]. - The company has not proposed any cash dividend distribution during the reporting period, despite having a positive profit available for distribution to shareholders[129]. - The company has not reported any risks during the supervisory activities of the board of supervisors in the reporting period[125]. Strategic Initiatives - The company plans to enhance R&D investment to develop new products and improve profitability, aiming to accelerate the trial production of the multifunctional pilot workshop project[85]. - The company aims to maintain its market share in existing products while expanding into new customer segments and optimizing product structure[84]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of CNY 500 million allocated for potential mergers and acquisitions[110]. - The management emphasized a commitment to sustainability, aiming for a 25% reduction in carbon emissions by 2025[110]. - The company plans to enhance its digital marketing strategy, expecting a 30% increase in online sales channels by the end of 2023[110].

证券代码：000953 证券简称：*ST 河化 广西河池化工股份有限公司投资者关系活动记录表 编号：2021-002 | --- | --- | --- | --- | --- | |------------------|----------------------------------------------------|---------------------------------------------------------------------------------------------|-------------|----------------------| | | | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | | | 类别 | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | ■其他（参加 2021 | 年广西辖区上市公司投资者网上集体接待 | | | | | 日暨 2020 | 年度业绩说明会活动） | | | | 参与单位名称及 | 参加 2021 | 年广 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥37,976,698.50, a decrease of 5.29% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥5,731,820.08, representing a significant decline of 1,452.50% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥5,795,516.42, a decrease of 11,086.85% compared to the previous year[5]. - Total operating revenue for the period was CNY 131,888,715.06, a decrease of 1.1% compared to CNY 133,381,231.81 in the previous period[18]. - Net profit for the third quarter was a loss of ¥4,041,708.17, compared to a profit of ¥3,866,625.39 in the same period last year, indicating a significant decline[20]. - Operating profit turned negative at ¥-4,024,899.09, down from ¥4,721,083.41 in the previous year[19]. - The company reported a total comprehensive income of ¥-4,041,708.17, compared to ¥3,866,625.39 in the previous year[20]. - Basic and diluted earnings per share were both ¥-0.0112, compared to ¥0.0090 in the same quarter last year[20]. Assets and Liabilities - The total assets at the end of the reporting period were ¥372,353,452.42, down 6.07% from the end of the previous year[5]. - Total assets decreased to CNY 372,353,452.42 from CNY 396,411,315.40, reflecting a decline of 6.1%[16]. - Total liabilities decreased to CNY 181,618,317.70 from CNY 202,272,965.76, a reduction of 10.2%[16]. - The company’s non-current assets increased slightly to CNY 246,701,910.38 from CNY 241,285,798.75, an increase of 2.4%[15]. - The company’s retained earnings showed a slight decline, with a balance of CNY -710,612,948.36 compared to CNY -706,515,946.95 in the previous period[16]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥3,538,796.92, a decrease of 55.69% compared to the same period last year[5]. - Cash flow from operating activities generated ¥3,538,796.92, a decrease of 55.7% compared to ¥7,985,606.47 in the prior year[21]. - Cash flow from investment activities yielded a net inflow of ¥24,919,237.25, up from ¥6,443,147.62 year-over-year[22]. - The company’s cash and cash equivalents at the end of the period totaled ¥64,153,407.11, down from ¥68,159,883.04 at the end of the previous year[22]. - Cash and cash equivalents increased to CNY 64,153,407.11 from CNY 35,685,903.67, representing an increase of 79.5%[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,695[10]. - The largest shareholder, Ningbo Yinyi Holdings Co., Ltd., held 23.76% of the shares, with 87,000,000 shares pledged[10]. Research and Development - The company's R&D expenses decreased by 46.19% year-on-year to ¥3,087,644.84, due to optimization of the R&D personnel structure[9]. - Research and development expenses decreased to ¥3,087,644.84 from ¥5,738,149.25, reflecting a reduction of approximately 46%[19]. Inventory and Operating Costs - The company's inventory increased by 45.05% to ¥34,548,875.93, primarily due to an increase in stock of finished goods[9]. - Inventory rose to CNY 34,548,875.93, up from CNY 23,818,434.02, indicating a growth of 45.2%[15]. - Total operating costs increased to ¥142,417,525.67 from ¥131,518,124.41, representing an increase of approximately 8.4% year-over-year[19]. Legal and Investment Activities - The company won a lawsuit against Alkaloida Chemical Company, receiving a total of USD 673,500 in goods and USD 271,401.39 in penalties[12]. - The company plans to invest CNY 44,519,300 in the technical transformation of production lines and multi-functional pilot workshops[13]. Credit Impairment - The company incurred a credit impairment loss of ¥5,165,633.90, significantly higher than ¥669,137.58 in the same period last year[19].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 93,912,016.56, representing a 0.67% increase compared to CNY 93,283,962.41 in the same period last year[24]. - The net profit attributable to shareholders decreased by 42.77% to CNY 1,634,818.67 from CNY 2,856,763.21 year-on-year[24]. - The net profit after deducting non-recurring gains and losses was CNY -3,340,425.88, a decline of 290.69% compared to CNY 1,751,745.52 in the previous year[24]. - Basic earnings per share decreased by 42.31% to CNY 0.0045 from CNY 0.0078 in the previous year[24]. - The weighted average return on equity was 0.92%, down 0.78% from 1.70% in the same period last year[24]. - The company reported a total investment income of CNY 569,366.44, contributing 18.77% to the total profit, primarily from the sale of bank wealth management products[47]. - The total comprehensive income for the first half of 2022 was CNY 1,999,808.03, down from CNY 3,349,624.24 in the same period of 2021, indicating a decrease of about 40.4%[138]. Cash Flow and Assets - The net cash flow from operating activities increased by 68.06% to CNY 12,395,475.38 from CNY 7,375,714.21 in the same period last year[24]. - The net cash flow from investment activities for the first half of 2022 was CNY 17,542,602.30, a decrease from CNY 19,423,406.20 in the same period of 2021, reflecting a decline of approximately 4.5%[140]. - The total cash and cash equivalents at the end of the first half of 2022 amounted to CNY 65,706,750.20, down from CNY 80,607,138.98 at the end of the first half of 2021, representing a decrease of about 18.5%[140]. - The company's total assets at the end of the reporting period were CNY 387,067,545.92, down 2.36% from CNY 396,411,315.40 at the end of the previous year[24]. - The net increase in cash and cash equivalents was CNY 30,020,846.53, representing a 17.79% increase from CNY 25,486,585.24 in the previous year[46]. Operational Highlights - The company is primarily engaged in the research, production, and sales of pharmaceutical intermediates and urea processing and sales[32]. - The operating cost increased by 21.99% to 87,946,455.24 yuan, primarily due to a higher proportion of urea sales, which have a higher cost[41]. - The company is focusing on adjusting its product structure and expanding its customer base in response to market challenges[39]. - The company emphasizes continuous R&D and innovation to improve efficiency and reduce costs in its pharmaceutical intermediate business[34]. - The company has established long-term partnerships with key raw material suppliers to mitigate supply chain fluctuations[34]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares[5]. - The total number of shares is 366,122,195, with 46,200,690 shares (12.62%) under limited sale conditions and 319,921,505 shares (87.38%) under unlimited sale conditions[110]. - The largest shareholder, Ningbo Yinyi Holdings Co., Ltd., holds 23.76% of the shares, totaling 87,000,000 shares, which are currently pledged and frozen[112]. - The company emphasizes the protection of shareholder rights, particularly for minority shareholders, by adhering to legal regulations and enhancing shareholder participation through online voting[77]. Environmental and Safety Measures - The company has implemented pollution control measures, with a wastewater treatment capacity of 500 tons per day, ensuring compliance with environmental standards[72]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[75]. - Safety production measures have been enhanced, with regular maintenance and training to meet safety production goals[78]. - Environmental protection efforts include the operation of wastewater treatment facilities that meet discharge standards, with over 90% data transmission rate for monitoring equipment[78]. Risks and Challenges - The company faces risks from drug procurement policies, which may lead to price declines in its products, and is taking measures to enhance product quality and reduce costs[62]. - The company is exposed to foreign exchange risks due to its export business, and plans to strengthen R&D and utilize financial tools to mitigate these risks[62]. - The controlling shareholder has been facing liquidity crises since 2019, with ongoing debt restructuring efforts[90]. Financial Reporting and Compliance - The semi-annual financial report has not been audited[86]. - The financial statements are prepared based on the assumption of going concern, with no significant doubts about the company's ability to continue operations[162]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect a true and complete picture of its financial status[163].

广西河池化工股份有限公司 2022 年第一季度报告全文 证券代码：000953 证券简称：河化股份 公告编号：2022-021 广西河池化工股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 40,969,366.74 | 46,757,837.67 | -12.38% | | 归属于上市公司股东的净利润（元） | -1,431,517.79 | 5,459,9 ...

Financial Performance - The company's operating revenue for 2021 was ¥162,273,039.66, a decrease of 33.36% compared to ¥243,512,663.64 in 2020[20] - The net profit attributable to shareholders for 2021 was ¥10,018,330.39, down 67.62% from ¥30,939,202.60 in the previous year[20] - Basic earnings per share for 2021 were ¥0.03, a decline of 66.67% from ¥0.09 in 2020[21] - The net cash flow from operating activities decreased by 90.00%, amounting to ¥6,710,748.57 compared to ¥67,130,814.12 in 2020[21] - The company reported a total of ¥7.72 million in non-recurring gains and losses for 2021, a significant recovery from a loss of approximately ¥7.54 million in 2020[27] - The company achieved a total operating revenue of ¥162,273,039.66 in 2021, a decrease of 33.36% compared to the previous year[43] - The net profit attributable to shareholders was ¥10,018,330.39, down 67.62% year-on-year[43] - The pharmaceutical intermediates segment generated ¥89,702,497.45, accounting for 55.28% of total revenue, reflecting a 41.67% decline from 2020[45] - The fertilizer business contributed ¥68,291,410.11, representing 42.08% of total revenue, with a decrease of 22.49% year-on-year[45] Business Transformation and Strategy - The company has undergone a significant business transformation since 2020, shifting its focus to the research, production, and sales of chemical raw materials and pharmaceuticals[18] - The company emphasizes the importance of market conditions in achieving its operational goals and future plans[4] - The company is focused on the R&D and production of pharmaceutical intermediates, with a strong emphasis on new product development and process improvement[35] - The company utilizes a centralized procurement model to improve cost efficiency and reduce supply chain volatility[37] - The production strategy includes both general production based on sales forecasts and customized production according to client specifications[37] Market and Demand - The demand for chloroquine side chains surged in 2020 due to the COVID-19 pandemic, leading to increased product demand and prices, although the market normalized in 2021[32] - The company faced challenges due to high raw material prices and unstable energy supply, impacting production cycles and costs[42] - The domestic revenue was ¥112,500,990.05, down 31.98% year-on-year, while overseas revenue decreased by 36.28% to ¥49,772,049.61[45] Research and Development - The company’s R&D expenses in 2021 were ¥7,703,278.92, a decrease of 9.24% compared to ¥8,487,368.41 in 2020, while the R&D expenses accounted for 4.75% of operating revenue[56] - The company completed the optimization of several new processes, including methyl silane and valproic acid, aiming for industrial production and new economic growth points[56][57] - The number of R&D personnel decreased by 7.14% from 56 in 2020 to 52 in 2021, while the proportion of R&D personnel increased from 27.18% to 32.53%[57] Governance and Compliance - The company has established a robust internal management system to ensure compliance with laws and regulations, enhancing governance standards[82] - The company prioritizes transparent information disclosure, ensuring all shareholders have equal access to relevant information[85] - The company actively manages investor relations through various communication channels, fostering a positive relationship with investors[85] - The company has maintained effective internal control over financial reporting without any significant deficiencies or important deficiencies[129] - The internal control audit report issued on April 30, 2022, confirmed that the company maintained effective internal controls in all material respects as of December 31, 2021[134] Shareholder Relations - The company held two shareholder meetings during the reporting period, ensuring equal rights for all shareholders, particularly minority shareholders[83] - The annual shareholders' meeting had a participation rate of 30.29% on May 18, 2021[88] - The first extraordinary shareholders' meeting had a participation rate of 43.76% on September 14, 2021[89] - The company has not reported any penalties from securities regulatory agencies for its current and recently departed directors, supervisors, and senior management[108] Environmental and Social Responsibility - The company has invested in environmental protection facilities and improved production processes to achieve energy conservation and emission reduction goals[147] - The company has not faced any administrative penalties related to environmental issues during the reporting period[145] - The company has not initiated any poverty alleviation or rural revitalization projects during the reporting period[148] Future Outlook - The company plans to enhance cooperation with downstream pharmaceutical clients and increase investment in technology development and business expansion[74] - New product development will focus on T51, T22, and T62 intermediates, with efforts to accelerate their market introduction[75] - The company anticipates risks from drug procurement policies that may lead to price declines for intermediate products, prompting a need for cost control and quality improvement[77] - The company has provided a revenue guidance of CNY 1.8 billion for the fiscal year 2022, which reflects an expected growth of 20%[95] Related Party Transactions and Commitments - The company has committed to avoid any form of fund occupation or illegal appropriation of assets from the listed company[153] - The company has pledged to ensure that no direct or indirect means will be used to seek control over the board of directors of the listed company[153] - The commitments made by the actual controller will remain valid unless they cease to be the controlling shareholder[150] - The company has undertaken to minimize related transactions and ensure they are conducted at market prices[150] Employee and Management Information - The total number of employees at the end of the reporting period is 182, with 16 in the parent company and 166 in major subsidiaries[122] - The company has a complete business operation system and does not engage in substantial competition with its controlling shareholders[87] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 2.0772 million CNY[111]

广西河池化工股份有限公司 2021 年第三季度报告 证券代码：000953 证券简称：河化股份 公告编号：2021-039 广西河池化工股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 增减 | | 比上年同期增减 | | 营业收入（元） | 40,097,269.40 | 24.06% | 133,381,231.81 | -40.01% ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥93,283,962.41, a decrease of 50.91% compared to ¥190,023,890.74 in the same period last year[20]. - The net profit attributable to shareholders was ¥2,856,763.21, down 93.73% from ¥45,572,911.22 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥1,751,745.52, a decline of 96.15% compared to ¥45,441,914.64 in the previous year[20]. - The net cash flow from operating activities was ¥7,375,714.21, representing an 83.71% decrease from ¥45,285,557.86 in the same period last year[20]. - Basic earnings per share were ¥0.0078, down 93.95% from ¥0.1290 in the previous year[20]. - The company's revenue for the reporting period was ¥93.28 million, a decrease of 50.91% compared to ¥190.02 million in the same period last year[36]. - The net profit for the reporting period was ¥334.96 million, down 93.18% from the previous year[36]. - The gross profit margin for the pharmaceutical intermediates segment was 44.64%, down 17.19% year-on-year, while the gross profit margin for the fertilizer business was 1.43%, down 0.20% year-on-year[40]. - The net cash flow from operating activities decreased by 83.71% to ¥7,375,714.21, primarily due to a reduction in sales revenue[40]. - The company's total operating revenue for the reporting period was ¥93,283,962.41, a decrease of 50.91% compared to ¥190,023,890.74 in the same period last year[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥382,243,744.99, an increase of 1.58% from ¥376,292,912.19 at the end of the previous year[20]. - The net assets attributable to shareholders at the end of the reporting period were ¥169,847,014.84, up 1.71% from ¥166,990,251.63 at the end of the previous year[20]. - The company's total assets included cash and cash equivalents of ¥80,607,138.98, representing 21.09% of total assets, primarily due to the redemption of bank wealth management products[45]. - The company's total liabilities increased to CNY 196,468,125.83 from CNY 193,866,917.27, reflecting a growth of about 0.8%[122]. - The company's non-current assets decreased to CNY 245,166,701.57 from CNY 248,794,081.79, showing a decline of approximately 1.1%[121]. - The company's total liabilities at the end of the period were CNY 701,900,568.72, indicating a high leverage ratio[144]. Research and Development - The company continues to conduct small-scale research and pilot projects, including ongoing optimization of the T53 (Nebivolol Epoxide) process to reduce raw material costs[36]. - The company has developed new processes for T55 (Valproic Acid) and T57 (N-desmethylclobazam), with T57 samples already sent to customers for validation[36]. - The company emphasizes R&D and has a dedicated project management system to improve efficiency and reduce costs[30]. - Research and development expenses amounted to ¥3,850,668.12, a decrease of 18.18% from ¥4,706,454.31 in the previous year[40]. - The company's research and development expenses for the first half of 2021 were CNY 3,850,668.12, a decrease of 18.19% from CNY 4,706,454.31 in the first half of 2020[128]. Market and Sales - Domestic sales accounted for 73.53% of total revenue, amounting to ¥68,588,445.33, while overseas sales accounted for 26.47%, totaling ¥24,695,517.08, reflecting decreases of 47.04% and 59.20% respectively[39]. - The company has a high market share and quality-leading products, with self-operated import and export rights[32]. - The company has a flexible production model that allows for customization based on client needs, particularly for Vitamin D3 intermediates[31]. - The company has maintained a stable relationship with major clients, which is crucial for its revenue stability[58]. Environmental and Regulatory Compliance - The company emphasizes environmental protection and has taken measures to control pollution during production processes[55]. - The company has completed the construction of pollution control facilities, including a waste gas collection and treatment system with a design capacity of 30,000 m³/h and a wastewater treatment plant with a design capacity of 500 t/d[69]. - The total discharge of chemical oxygen demand (COD) is 1.55 t/a, which is below the approved discharge limit of 2.57 t/a, indicating no exceedance[69]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[73]. - The company has submitted a self-monitoring plan for environmental protection, which includes monitoring of wastewater, waste gas, and noise pollution[72]. Corporate Governance - The company has not made any changes to its board of directors or senior management during the reporting period[64]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[81]. - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[77]. - The semi-annual financial report has not been audited[79]. Financial Management - The company has a receivable from related parties amounting to 10,683.57 million CNY, with an interest rate of 4.35%[87]. - The company has a payable to related parties totaling 2,282.93 million CNY, also at an interest rate of 4.35%[87]. - The company utilized related party borrowings primarily for short-term cash flow management, ensuring operational stability without impacting financial results[87]. - The company has invested 7,650 million CNY in bank wealth management products, with an outstanding balance of 704.6 million CNY[95]. - The company reported a total share count of 366,122,195, with 25,862,068 shares released from lock-up on March 26, 2021[101]. Future Outlook - The company plans to strengthen its market expansion and product development strategies to mitigate risks associated with high customer concentration[58]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[144].